ID

35259

Description

Ombitasvir/ABT-450/Ritonavir (Ombitasvir/ABT-450/r) With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatment Experienced Genotype 1a Hepatitis C Virus Infected Adults; ODM derived from: https://clinicaltrials.gov/show/NCT02476617

Link

https://clinicaltrials.gov/show/NCT02476617

Keywords

Versions (1)
  1. 2/25/19 2/25/19 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

February 25, 2019

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Chronic Hepatitis C NCT02476617

English

Eligibility Chronic Hepatitis C NCT02476617

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. screening laboratory result indicating hcv gt1a infection.
Description

Hepatitis C Genotype Laboratory test result

Data type

boolean

Alias
UMLS CUI [1,1]
C0019196
UMLS CUI [1,2]
C0017431
UMLS CUI [1,3]
C0587081
2. chronic hcv infection.
Description

Hepatitis C, Chronic

Data type

boolean

Alias
UMLS CUI [1]
C0524910
3. subjects must be non-cirrhotic.
Description

Study Subject Non-cirrhotic

Data type

boolean

Alias
UMLS CUI [1,1]
C0681850
UMLS CUI [1,2]
C0439687
4. subjects must be treatment-naïve or have documentation that they were adherent to prior pegifn/rbv combination therapy and meet the criteria of prior pegifn/rbv treatment failure.
Description

Therapy naive | PEGINTERFERON/RIBAVIRIN | PEGINTERFERON/RIBAVIRIN Treatment failure

Data type

boolean

Alias
UMLS CUI [1]
C0919936
UMLS CUI [2]
C1875630
UMLS CUI [3,1]
C1875630
UMLS CUI [3,2]
C0162643
5. subjects must meet specific human leukocyte antigen (hla) allele requirements.
Description

Human leukocyte antigen allele Specific

Data type

boolean

Alias
UMLS CUI [1,1]
C0555907
UMLS CUI [1,2]
C0205369
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. women who are pregnant or breastfeeding.
Description

Pregnancy | Breast Feeding

Data type

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
2. positive test result for hepatitis b surface antigen (hbsag) or anti-human immunodeficiency virus antibody (hiv ab) positive immunoassay.
Description

Hepatitis B surface antigen positive Immunoassay | HIV antibody positive Immunoassay

Data type

boolean

Alias
UMLS CUI [1,1]
C0149709
UMLS CUI [1,2]
C0020980
UMLS CUI [2,1]
C0920548
UMLS CUI [2,2]
C0020980
3. clinically significant abnormalities or co-morbidities, other than hcv infection, that make the subject unsuitable for this study or treatment.
Description

Abnormality Study Subject Participation Status Inappropriate | Comorbidity Study Subject Participation Status Inappropriate | Exception Hepatitis C

Data type

boolean

Alias
UMLS CUI [1,1]
C1704258
UMLS CUI [1,2]
C2348568
UMLS CUI [1,3]
C1548788
UMLS CUI [2,1]
C0009488
UMLS CUI [2,2]
C2348568
UMLS CUI [2,3]
C1548788
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0019196
4. current enrollment in another interventional clinical study, previous enrollment in this study, prior or current use of any investigational or commercially available anti-hcv agents other than pegifn or rbv (including previous exposure to abt-450, ombitasvir, or dasabuvir), or receipt of any investigational product within 6 weeks prior to study drug administration.
Description

Study Subject Participation Status | Interventional Study | Anti-hepatitis C (HCV) Agents | Exception PEGINTERFERON | Exception Ribavirin | Exposure to ABT-450 | Exposure to Ombitasvir | Exposure to Dasabuvir | Investigational New Drugs

Data type

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2]
C3274035
UMLS CUI [3]
C4324240
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C0982327
UMLS CUI [5,1]
C1705847
UMLS CUI [5,2]
C0035525
UMLS CUI [6,1]
C0332157
UMLS CUI [6,2]
C3712108
UMLS CUI [7,1]
C0332157
UMLS CUI [7,2]
C3852670
UMLS CUI [8,1]
C0332157
UMLS CUI [8,2]
C3852512
UMLS CUI [9]
C0013230
5. history or solid organ transplant.
Description

Solid organ transplant

Data type

boolean

Alias
UMLS CUI [1]
C0730400
6. screening laboratory analysis that shows abnormal results.
Description

Laboratory test result abnormal

Data type

boolean

Alias
UMLS CUI [1]
C0438215
Back to the top of the page

Similar models

Eligibility Chronic Hepatitis C NCT02476617

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Hepatitis C Genotype Laboratory test result
Item
1. screening laboratory result indicating hcv gt1a infection.
boolean
C0019196 (UMLS CUI [1,1])
C0017431 (UMLS CUI [1,2])
C0587081 (UMLS CUI [1,3])
Hepatitis C, Chronic
Item
2. chronic hcv infection.
boolean
C0524910 (UMLS CUI [1])
Study Subject Non-cirrhotic
Item
3. subjects must be non-cirrhotic.
boolean
C0681850 (UMLS CUI [1,1])
C0439687 (UMLS CUI [1,2])
Therapy naive | PEGINTERFERON/RIBAVIRIN | PEGINTERFERON/RIBAVIRIN Treatment failure
Item
4. subjects must be treatment-naïve or have documentation that they were adherent to prior pegifn/rbv combination therapy and meet the criteria of prior pegifn/rbv treatment failure.
boolean
C0919936 (UMLS CUI [1])
C1875630 (UMLS CUI [2])
C1875630 (UMLS CUI [3,1])
C0162643 (UMLS CUI [3,2])
Human leukocyte antigen allele Specific
Item
5. subjects must meet specific human leukocyte antigen (hla) allele requirements.
boolean
C0555907 (UMLS CUI [1,1])
C0205369 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI)
Pregnancy | Breast Feeding
Item
1. women who are pregnant or breastfeeding.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Hepatitis B surface antigen positive Immunoassay | HIV antibody positive Immunoassay
Item
2. positive test result for hepatitis b surface antigen (hbsag) or anti-human immunodeficiency virus antibody (hiv ab) positive immunoassay.
boolean
C0149709 (UMLS CUI [1,1])
C0020980 (UMLS CUI [1,2])
C0920548 (UMLS CUI [2,1])
C0020980 (UMLS CUI [2,2])
Abnormality Study Subject Participation Status Inappropriate | Comorbidity Study Subject Participation Status Inappropriate | Exception Hepatitis C
Item
3. clinically significant abnormalities or co-morbidities, other than hcv infection, that make the subject unsuitable for this study or treatment.
boolean
C1704258 (UMLS CUI [1,1])
C2348568 (UMLS CUI [1,2])
C1548788 (UMLS CUI [1,3])
C0009488 (UMLS CUI [2,1])
C2348568 (UMLS CUI [2,2])
C1548788 (UMLS CUI [2,3])
C1705847 (UMLS CUI [3,1])
C0019196 (UMLS CUI [3,2])
Study Subject Participation Status | Interventional Study | Anti-hepatitis C (HCV) Agents | Exception PEGINTERFERON | Exception Ribavirin | Exposure to ABT-450 | Exposure to Ombitasvir | Exposure to Dasabuvir | Investigational New Drugs
Item
4. current enrollment in another interventional clinical study, previous enrollment in this study, prior or current use of any investigational or commercially available anti-hcv agents other than pegifn or rbv (including previous exposure to abt-450, ombitasvir, or dasabuvir), or receipt of any investigational product within 6 weeks prior to study drug administration.
boolean
C2348568 (UMLS CUI [1])
C3274035 (UMLS CUI [2])
C4324240 (UMLS CUI [3])
C1705847 (UMLS CUI [4,1])
C0982327 (UMLS CUI [4,2])
C1705847 (UMLS CUI [5,1])
C0035525 (UMLS CUI [5,2])
C0332157 (UMLS CUI [6,1])
C3712108 (UMLS CUI [6,2])
C0332157 (UMLS CUI [7,1])
C3852670 (UMLS CUI [7,2])
C0332157 (UMLS CUI [8,1])
C3852512 (UMLS CUI [8,2])
C0013230 (UMLS CUI [9])
Solid organ transplant
Item
5. history or solid organ transplant.
boolean
C0730400 (UMLS CUI [1])
Laboratory test result abnormal
Item
6. screening laboratory analysis that shows abnormal results.
boolean
C0438215 (UMLS CUI [1])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial